Dapagliflozin
ACC announces lineup of 2025 Scientific Session late-breakers
The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March 29-31 in Chicago and online.
Sodium-glucose inhibitor use in PAH may have mortality benefit
BOSTON — Fewer patients with pulmonary arterial hypertension died at three time points with use of a sodium-glucose cotransporter-2 inhibitor, according to data presented at the CHEST Annual Meeting.
Medicare announces price cuts for 10 drugs in first round of drug price negotiations
The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.
Top in endocrinology: New OTC glucose monitors; exposure to endocrine-disrupting chemicals
The FDA recently cleared two over-the-counter continuous glucose monitoring systems, one for adults with type 2 diabetes who do not use insulin and another for adults without diabetes who are looking to improve overall health and wellness.
FDA approves dapagliflozin for children and adolescents with type 2 diabetes
The FDA approved the SGLT2 inhibitor dapagliflozin to improve glycemic control among children and adolescents aged 10 years and older with type 2 diabetes, according to an industry press release.
Part of the Healio Network
Sodium-Glucose Transporter 2 (SGLT2) Inhibitors Topic Review
As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a]
Dapagliflozin reduces diuretic doses, daily uptitrations and hospital stay for acute HF
Despite dapagliflozin not improving diuretic efficiency in the setting of acute HF hospitalization, it was associated with fewer diuretic doses to achieve the same weight change as usual care and shorter hospital stay, researchers reported.
Mortality benefit derived from SGLT2 inhibition could extend to HF with improved EF
Dapagliflozin plus guideline-directed medical therapy may reduce CV death in patients with HF with improved ejection fraction by lowering risk for sudden death, researchers reported.
Top cardiology news in 2023: A year of firsts for CVD treatments, procedures, devices
Healio | Cardiology Today compiled a list of some of the most important news in cardiology from 2023.
Women at significant risk for urinary, genital infections while using SGLT2i
SAN DIEGO — Women with autoimmune and rheumatic conditions are at a significant risk for adverse events during treatment with sodium glucose cotransporter 2 inhibitors, according to data presented at ACR Convergence 2023.